title: SP600125, a JNK inhibitor, suppresses growth of JNK-inactive glioblastoma cells through cell-cycle G2/M phase arrest.
abstract: SP600125 is a well studied inhibitor of c-Jun N-terminal kinase (JNK). Its direct biochemical effects on JNK-inactive tumor cells are usually ignored. In this study, we investigated the effects of SP600125 on JNK-inactive U251 human glioblastoma cells. Our results demonstrate that, 20 microM or more SP600125 can induce significant cell growth inhibition and cell-cycle G2/M phase arrest in U251 cells. Interestingly, we also found that SP600125 can stop the duplicated chromosomes from separating into two cells and the karyokinesis progression. Our study opened up a new perspective for further studies involved in JNK inhibitors or anti-glioma therapy.
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing City, Nanjing, China.
authors.forename: J Y
authors.initials: JY
authors.lastname: Li
authors.forename: J Y
authors.initials: JY
authors.lastname: Huang
authors.forename: B
authors.initials: B
authors.lastname: Xing
authors.forename: K W
authors.initials: KW
authors.lastname: Ren
authors.forename: M
authors.initials: M
authors.lastname: Li
authors.forename: D
authors.initials: D
authors.lastname: Wei
authors.forename: P Y
authors.initials: PY
authors.lastname: Gu
authors.forename: G
authors.initials: G
authors.lastname: Chen
authors.forename: B
authors.initials: B
authors.lastname: Gu
authors.forename: G F
authors.initials: GF
authors.lastname: Zhang
authors.forename: W X
authors.initials: WX
authors.lastname: Hu
mesh_terms: D000873:Anthracenes / Q000494:pharmacology*; D001562:Benzimidazoles; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D016203:CDC2 Protein Kinase / Q000378:metabolism; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000187:drug effects / Q000648:ultrastructure; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005434:Flow Cytometry; D005456:Fluorescent Dyes; D059565:G2 Phase Cell Cycle Checkpoints / Q000187:drug effects*; D005909:Glioblastoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006801:Humans; D059566:M Phase Cell Cycle Checkpoints / Q000187:drug effects*; D048670:MAP Kinase Kinase 4 / Q000037:antagonists & inhibitors*; D014617:Vacuoles / Q000187:drug effects / Q000648:ultrastructure
chemical_list: D000873:Anthracenes; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D005456:Fluorescent Dyes; C432165:pyrazolanthrone; D016203:CDC2 Protein Kinase; D048670:MAP Kinase Kinase 4; C017807:bisbenzimide ethoxide trihydrochloride